Hdac6 inhibitors - Articles - Page 2

Neurology/psychiatric

Equity investment in Eikonizo supports HDAC6 inhibitor work

Dec. 10, 2024

Eikonizo Therapeutics Inc. has secured an equity investment from Novo Nordisk A/S.

Neurology/psychiatric

HDAC6 inhibitors described in Miralinc Pharma patent

Oct. 9, 2024

Miralinc Pharma Inc. has patented new heterocyclic selective histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of type 2 Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, among others.

Neurology/psychiatric

Chong Kun Dang Pharmaceutical identifies new HDAC6 inhibitors

Sep. 25, 2024

Chong Kun Dang Pharmaceutical Corp. has disclosed 1,3,4-oxadiazole-containing compounds acting as histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of prion diseases, asthma, psoriasis, inflammatory bowel disease, autosomal dominant polycystic kidney, stroke, Charcot-Marie-Tooth disease and uveitis, among others.

Neurology/psychiatric

HDAC inhibitor improves Charcot-Marie-Tooth disease in mice

July 8, 2024

Therapeutics for peripheral neuropathies, such as Charcot-Marie-Tooth (CMT) disease, are still quite limited and focus on managing symptoms. Augustine Therapeutics NV has presented an orally available histone deacetylase 6 (HDAC6) inhibitor, AGT-100216, for the treatment of CMT. AGT-100216 was designed to work through improving axonal regeneration and nerve functional restoration.

Cancer

University of Toronto discovers new HDAC6 inhibitors

March 12, 2024

University of Toronto has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders.

Immuno-oncology

Avstera’s AVS-100 cleared to enter clinic for solid tumors

Dec. 19, 2023

Avstera Therapeutics Corp. has received FDA clearance of its IND application for HDAC6 inhibitor AVS-100. Avstera intends to initiate a phase Ia/b trial in the first half of 2024 to evaluate AVS-100 alone and in combination with pembrolizumab in locally advanced or metastatic solid tumors.

Neurology/Psychiatric

HDAC6 inhibitor ACY-738 shows protective effects in axonal degeneration

Dec. 12, 2023

Microtubule acetylation and impaired axonal transport have been proposed as mechanisms causing amyotrophic lateral sclerosis (ALS). Furthermore, histone deacetylase 6 (HDAC6) is known to play a role in acetylation of α-tubulin, a subunit of microtubules. ACY-738 is an HDAC6 inhibitor that has been reported to slow neuron degeneration in Alzheimer’s disease and ALS models by increasing acetylation of α-tubulin.

Neurology/Psychiatric

Oryzon Genomics awarded grant to support preclinical development of ORY-4001 in ALS

Dec. 5, 2023

Oryzon Genomics SA has been awarded a $498,690 grant by the ALS Association to support the regulatory preclinical development of ORY-4001, a highly selective histone deacetylase 6 (HDAC6) inhibitor, for amyotrophic lateral sclerosis (ALS).

Cancer

Suzhou Genhouse Bio patents new HDAC inhibitors

Nov. 9, 2023

Work at Suzhou Genhouse Bio Co. Ltd. has led to the discovery of oxadiazole compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be potentially useful for the treatment of cancer, asthma, Alzheimer’s disease, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.

Chong Kun Dang scores its ‘largest ever’ $1.3B deal with Novartis for CKD-510

Nov. 7, 2023

By Marian (YoonJee) Chu

South Korea’s Chong Kun Dang Pharmaceuticals Corp. said that it struck a deal potentially worth $1.3 billion with Swiss pharma giant Novartis AG for its CKD-510 candidate for neurological and cardiovascular diseases, propelling its shares upward 26.11% by market closing of Nov. 6. With the “largest ever” deal in its history, shares of the Seoul-based pharmaceutical (KOSPI:185750) on the Korea Exchange rose by 26.11%, or ₩26,500, closing at ₩128,000 ($98.70).